SAMSUNG BIOLOGICS CO.,LTD. Q3 revenue KRW 1,490.3 billion, operating profit KRW 640.1 billion
AI summary · Not investment advice
Samsung Biologics sold KRW 1,490.3 billion in Q3 and earned KRW 640.1 billion from its main business, up 1.0% from a year earlier and up 9.1% from the previous quarter.
Operating profit · 3 months
KRW 640.1 billion
Key facts
- Revenue (3 months)
- KRW 1.5 trillion
- Net income (3 months)
- KRW 391.1 billion
- Period
- Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
- Revenue (prior-year 3 months)
- KRW 1.3 trillion
- Revenue (year to date)
- KRW 4.1 trillion
- Operating profit (prior-year 3 months)
- KRW 633.5 billion
- Operating profit (year to date)
- KRW 1.8 trillion
- Net income (prior-year 3 months)
- KRW 574.5 billion
- Net income (year to date)
- KRW 1.3 trillion
Commentary
AI commentary · Not investment advice
What happened
Samsung Biologics reported its third-quarter results on a consolidated basis, covering the 3 months and the year to date from January 1 to September 30, 2026.
In the company's terms
Revenue for the 3 months was KRW 1,490.3 billion. That is 18.5% higher than the same period a year earlier (KRW 1,257.5 billion). It is also 12.8% higher than the previous quarter.
What changes for shareholders
Operating profit (profit from the core business) for the 3 months was KRW 640.1 billion. That is 1.0% higher than a year earlier (KRW 633.5 billion) and 9.1% higher than the previous quarter.
Net income (the final profit after taxes and all other costs) for the 3 months was KRW 391.1 billion. That is 31.9% lower than a year earlier (KRW 574.5 billion) and 9.2% lower than the previous quarter.
For the year to date, revenue was KRW 4,068.4 billion, operating profit was KRW 1,807.3 billion, and net income was KRW 1,291.0 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
S